Early Data From Novavax COVID-19 Vaccine Shows Promise

Nova VAX, a biotechnology company, released its phase one data showing that their vaccine, when administered in two doses, led to the development of four times more antibodies in test subjects compared to those with previous COVID-19 antibodies. The vaccine was deemed safe, with no serious side effects, only mild reactions lasting about two days. The findings have been submitted to a medical journal but are yet to be reviewed by external scientists.

What was the duration of the mild side effects experienced by some subjects?

What is the current status of the findings submitted by Nova VAX?